This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesTrendsBuy This Stock About Aptose Biosciences Stock (NASDAQ:APTO) Get Aptose Biosciences alerts:Sign Up Key Stats Today's Range$1.71▼$1.7150-Day Range$1.71▼$6.8652-Week Range$1.35▼$50.10VolumeN/AAverage Volume227,964 shsMarket Capitalization$3.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APTO Stock News HeadlinesAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral PresentationJune 15 at 7:30 AM | globenewswire.comAptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi PharmaceuticalMay 29, 2026 | financialpost.comFA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker. That window has closed - but the next opportunity may still be open. Trader Lance Ippolito has released a free SpaceX Investing Blackbook covering pre-IPO positioning plays, the space stock Goldman Sachs, BlackRock, and Morgan Stanley are loading up on, and the chip supplier Starlink satellites depend on.June 18 at 1:00 AM | InvestPub (Ad)Aptose Reports First Quarter 2026 ResultsMay 13, 2026 | financialpost.comFAptose Reports First Quarter 2026 ResultsMay 13, 2026 | globenewswire.comAptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi PharmaceuticalApril 30, 2026 | markets.businessinsider.comAptose Hanmi Acquisition Closing Delayed Pending Korean ApprovalsApril 30, 2026 | tipranks.comAptose Biosciences, Inc.: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year ...April 1, 2026 | finanznachrichten.deSee More Headlines APTO Stock Analysis - Frequently Asked Questions How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($12.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($17.40) by $4.50. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA). Company Calendar Last Earnings8/08/2024Today6/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year Founded2014Profitability EPS (Trailing Twelve Months)($89.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-5,683.22% Return on Assets-300.44% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-9.00Miscellaneous Outstanding Shares2,141,000Free Float63,446,000Market Cap$3.66 million OptionableNo Data Beta1.04 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:APTO) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...Golden Portfolio | SponsoredDo NOT buy or sell SPCX before reading thisSpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredTesla's robot factory goes live this summerOn Tesla's Q1 2026 earnings call, Elon Musk confirmed Optimus robot production at the Fremont factory begins l...StocksToTrade | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
